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Idiopathic pulmonary fibrosis (IPF) is the most common and lethal of the idiopathic interstitial 
pneumonias with an estimated 5-year survival of approximately 20%. In the last two decades our 
understanding of disease pathogenesis has substantially evolved and novel compounds have been 
developed consequent to the increasing knowledge of the mechanisms underlying disease pathobiology. 
The disease appears to be driven - following chronic injury - by abnormal/dysfunctional alveolar 
epithelial cells that promote fibroblast recruitment and proliferation, resulting in scarring of the lung 
and irreversible loss of function. With very few exceptions, clinical trials evaluating novel potential 
therapies have provided disappointing results. More recently, pirfenidone and nintedanib, two 
compounds with pleiotropic mechanisms of action, have proven effective in slowing functional decline 
and disease progression in IPF patients with mild to moderate functional impairment, highlighting the 
importance of timely diagnosis and administration of treatment in early stages of disease. However, due 
to the complexity and uncertainties intrinsic to IPF, it is essential that each therapeutic strategy be 
tailored to the individual patient, after evaluation of potential benefits and risks. This article provides 
an overview of the most recent clinical trials in IPF and discusses how their results are going to change 
the clinical and clinical research landscape in IPF. A number of agents with high potential are currently 
being tested and many more are ready for clinical trials. Their completion is critical for achieving the 
ultimate goal of curing patients with IPF. 
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ANCOVA: analysis of covariance 
DLCO: diffusing capacity of the lung for carbon monoxide 
DPLD: diffuse parenchymal lung disease 
ECM: extracellular matrix 
EMA: European Medicines Agency  
FDA: Food and Drug Administration  
FEV1: forced expiratory volume in one second  
FGF: fibroblast growth factor 
FVC: forced vital capacity 
GRADE: Grading of Recommendations Assessment, Development and Evaluation  
GSH: glutathione 
IIP: idiopathic interstitial pneumonia 
IPF: idiopathic pulmonary fibrosis 
LOCF: last observation carried forward 
NAC: N-acetylcysteine 
PDGF: platelet-derived growth factor  
PFS: progression-free survival 
RCT: randomized controlled trial 
SGRQ: St. George’s Respiratory Questionnaire  
6MWT: 6-minute walk test 
TGF-β: transforming growth factor-β 
TNF-α: tumour necrosis factor-α 
UIP: usual interstitial pneumonia 
VC: vital capacity 


















Diffuse parenchymal lung diseases (DPLDs) represent a heterogeneous collection of disorders 
characterized by varying patterns of inflammation and fibrosis but often sharing similar clinical, 
radiological and physiological features (Travis et al., 2013). While some forms of DPLDs are 
associated with environmental or occupational exposures (e.g., inhalation of fibrogenic dusts or 
aerosolized organic antigens), connective tissue diseases (e.g., rheumatoid arthritis, or systemic 
sclerosis), drug toxicity (e.g., amiodarone, or methotrexate), or radiation, idiopathic interstitial 
pneumonias (IIPs) are of unknown etiology and are thought to result from a complex interaction 
between host (genetic) factors and environmental triggers, including cigarette smoke (Spagnolo et al., 
2014).  
Idiopathic pulmonary fibrosis (IPF), the most common of the IIPs, is a chronic progressive disease, 
which primarily occurs in older adults (typically current or ex-smoking males over 60 years of age) and 
manifests with shortness of breath. In the US only, IPF affects between 150,000-200,000 people, and as 
many as 40,000 people die from IPF each year (Raghu et al., 2014). Similar incidence, prevalence and 
mortality rates have been reported in Europe (Navaratnam et al., 2011). The diagnosis of IPF requires 
the exclusion of all known causes of pulmonary fibrosis and the presence of a usual interstitial 
pneumonia (UIP) pattern, which is defined radiologically by subpleural, basal-predominant reticular 
abnormalities and honeycombing, with or without traction bronchiectasis (Figure 1), and histologically 
by patchy involvement of the lung parenchyma by fibrosis and honeycombing in a predominantly 
subpleural/paraseptal distribution and presence of fibroblastic foci (Figure 2) (Raghu et al., 2011). The 
disease is relentlessly progressive with a median survival time in retrospective longitudinal studies of 3 
to 5 years from the time of diagnosis (Bjoraker et al., 1998; Flaherty et al., 2002; Nicholson et al., 
2000; King et al., 2001). Although the population outcome for patients diagnosed with IPF is consistent 
across studies undertaken in different countries and continents, it remains difficult to predict the rate of 













Understanding of the pathogenesis of IPF has improved substantially in the last decade. Initially 
thought of as a predominantly inflammatory process, IPF appears instead to be driven by persistent 
alveolar epithelial cell (AEC) microinjury followed by an aberrant wound healing response (e.g., 
expansion of lung fibroblasts and myofibroblasts with secretion of excessive amounts of extracellular 
matrix (ECM) components), resulting in scarring of the lung, architectural distortion and irreversible 
loss of function (King et al., 2011). However, the mechanisms by which an initial injury triggers and 
perpetuates the fibrotic process are still debating. Recent clinical trials have therefore shifted their 
focus from antiinflammatory and immunosuppressant compounds to molecules targeting components 
of the wound healing cascade and fibrogenesis. Nonetheless, despite this shift results have been mostly 
disappointing, probably because of the plethora of mediators and signalling pathways likely to be 
involved in IPF pathogenesis (Maher, 2012). As such, the only care options which are endorsed by 
current evidence-based guidelines are oxygen therapy, pulmonary rehabilitation, lung transplantation 
and enrolment in clinical trials (Raghu et al., 2011). 
Since the publication of this guideline document, pirfenidone, which had been on the market in Japan 
since 2008, has been approved for the treatment of IPF initially in Europe, India and Canada, and 
recently by the US Food and Drug Administration (FDA) following prior rejection due to what was 
considered conflicting evidence of efficacy (Noble et al., 2011). On the same day, October 15 2014, the 
FDA also approved nintedanib to treat IPF. Both drugs reduce functional decline and disease 
progression in patients with mild to moderate functional impairment, highlighting the importance of 
timely diagnosis and administration of treatment in early stages of disease. 
This article provides an overview of the most recent clinical trials in IPF and discusses how these 
landmark studies are going to change the therapeutic landscape for this devastating disease. 













The management of patients with IPF is largely based on the recommendations of recent evidence-
based guidelines (Raghu et al., 2011). These recommendations have been made based on the quality of 
available data as assessed by the American Thoracic Society GRADE (Grading of Recommendations 
Assessment, Development and Evaluation) methodology (Schunemann et al., 2006). According to 
current guidelines, no treatment is recommended for patients with IPF (Table 1). Conversely, the 
guideline document makes strong recommendations against the use of most therapies by virtue of 
either lack of sufficient-quality data or clear evidence of inefficacy. Some pharmacological agents 
(combination of N-acetylcysteine [NAC]/prednisone/azathioprine; NAC monotherapy; warfarin; and 
pirfenidone) received a weak recommendation against their use (e.g., the majority of patients would not 
want the intervention, but it could represent a reasonable therapeutic choice in a minority of them), 
which could be interpreted as an endorsement for the use of that particular treatment, even if only in a 
minority of patients. However, since the publication of the 2011 guidelines, more robust and better-
quality data have become available and some of these recommendations will change in the near future. 
Specifically, combination of NAC/prednisone/azathioprine (Idiopathic Pulmonary Fibrosis Clinical 
Research Network, 2012) and warfarin (Noth et al., 2012) have been shown to be unsafe in patients 
with IPF whereas NAC monotherapy has no effect in preserving forced vital capacity (FVC) 
(Idiopathic Pulmonary Fibrosis Clinical Research Network, 2014). Similarly, a number of other agents, 
which were investigational at the time of the guideline document publication, have since proven to be 
ineffective or even harmful (e.g., ambrisentan; Raghu et al., 2013a) and no longer represent a 
therapeutic option for IPF patients. Conversely, recent data confirm that pirfenidone slows the 
deterioration in lung function and reduces disease progression in IPF (King et al., 2014a). Moreover, a 
phase 2 and two phase 3 clinical trials have, since the release of the guidelines, been published 
demonstrating the efficacy of the tyrosine kinase inhibitor, nintedanib, as a treatment for IPF (Richeldi 














3. How we got here and why did it take so long? 
In the last decade, a number of high-quality clinical trials have been conducted in IPF but the results 
have mostly been disappointing (Table 2). Several factors are, at least partially, responsible for such 
high rate of failure. These include; 
Animal models. Over the years, numerous agents have been shown to inhibit experimentally-induced 
lung fibrosis in mice. Yet,  of these >100 compounds showing efficacy in rodent models only two have 
demonstrated a comparable anti-fibrotic effect in humans. This is mainly because the bleomycin model, 
the most widely used model of experimentally-induced pulmonary fibrosis, recapitulates only partially 
the phenotype of progressive pulmonary fibrosis seen in IPF (Moeller et al., 2008). Furthermore, all 
animal models of fibrosis comprise a defined injury which, after a period of time, results in the 
development of self-limiting and at least partially resolving fibrosis. In the case of the bleomycin 
model, the initial insult with bleomycin gives rise to widespread epithelial cell apoptosis and necrosis, 
which in turn triggers a marked neutrophilic inflammatory response. The extent of epithelial cell death 
and the subsequent inflammatory response determine the severity of the fibrosis that develops. 
Prophylactic dosing of animals (i.e., before or within 7 days of bleomycin administration), with 
compounds which either inhibit apoptosis or attenuate inflammation, results in reduced fibrosis. As a 
consequence, many compounds have, in the past, erroneously been ascribed anti-fibrotic properties 
when in reality their effects were either antiinflammatory or anti-apoptotic. The use of therapeutic 
dosing in animal models of fibrosis will hopefully enhance the value of such in vivo experiments in the 
process of anti-fibrotic drug discovery in the future (Maher and Wells, 2009). 
Imperfect knowledge of disease pathogenesis. Concepts of disease pathogenesis have evolved from 
chronic inflammation to current paradigms of a multifactorial and heterogeneous process in which a 













epithelium vulnerable to a variety of insults. Injured type II AECs, in an attempt to restore functional 
integrity, release cytokines and growth factors, which promote aberrant recruitment and activation of 
apoptosis-resistant fibroblasts, the key mediators of fibrotic tissue remodeling. The end result is the 
exaggerated production of ECM components leading to progressive tissue remodelling and scarring 
(with inevitable loss of function) rather than normal repair (Maher, 2012; Selman and Pardo, 2014). 
Accordingly, it is only recently that clinical research in IPF has shifted focus from immunomodulatory 
to anti-fibrotic and anti-proliferative compounds.  
Target selection/redundancy of pathway targeting. IPF is characterized by abnormalities in multiple 
pathways involved in the wound healing process, many of which display considerable redundancy. 
Therefore, identifying therapeutic targets is extremely challenging. Numerous clinical trials have 
demonstrated that inhibiting individual mediators or signalling pathways is largely ineffective in 
slowing the inexorable progression of IPF, whereas more efficacious compounds (e.g., pirfenidone and 
nintedanib) are pleiotropic in their anti-fibrotic properties. 
Development and performance of IPF clinical trials. A number of components are necessary to the 
design and implementation of a successful clinical trial in IPF, not least of which are precise disease 
definition and established diagnostic criteria. In both the INPULSIS and the ASCEND trials, central 
review of the diagnosis of IPF performed by radiologists and pathologists experienced in interstitial 
lung disease allowed the inclusion of well-defined populations of patients. Indeed, a treatment effect is 
more likely to be seen in homogeneous IPF population.  
Pharmaceutical company interest. Historically, the pharmaceutical industry has been reluctant to invest 
in research and development of drugs for rare diseases like IPF (Spagnolo et al., 2013). Yet, clinical 
trials can be pursued, almost exclusively, by industry because of the enormous financial investment and 
logistic network required for successful drug development. The last decade has witnessed a growing 













only been possible thanks to the tremendous concerted effort of dedicated academic 
researchers/clinicians, patient organizations, health authorities and pharmaceutical companies. 
 
4. What have we learned from negative studies? 
Each of the negative clinical trials in IPF has been a source of great disappointment. However, the 
cumulative knowledge derived from these trials has been instrumental in building the foundation which 
underpins the recent IPF trial successes. It is important to realize that the first true randomized placebo 
controlled trial in IPF was only published as recently as 2004 (Raghu et al., 2004). This phase 2b study 
of interferon-γ-1b used a composite primary endpoint of progression-free survival (PFS); this was 
defined by either death, a >10% decline in FVC or a >5 mmHg rise in alveolar to arterial (a-A) oxygen 
gradient. This particular composite end point has never been re-used, in part because the change in a-A 
gradient proved to have poor reproducibility. Instead, subsequent late-phase IPF trials have used a 
variety of primary endpoints including survival time, change in 6-minute walk distance, change in 
lowest 6-minute walk saturation, change in FVC and a range of PFS composites. In recent times studies 
have increasingly used change in FVC as their primary outcome measure. This evolution in the use of 
primary endpoints has reflected a growing understanding - all of which has been derived from analysis 
of clinical trial data - of the variability, reproducibility and relationship to change in disease status of 
the various clinical measures, which can be applied to individuals with IPF (du Bois et al., 2012). 
Furthermore, the large datasets generated by multiple trials has enabled estimates to be made of the 
minimum clinically significant change in measures such as FVC and 6-minute walk distance (du Bois 
et al., 2011a; du Bois et al., 2014; du Bois et al., 2011b). Lessons have not only been learnt regarding 
the choice of efficacy endpoints for IPF studies but also in how to best measure those end-points, 
especially FVC. Most late-phase IPF studies now provide the same standardized spirometry equipment 













digital technology has permitted central assessment of the quality of individual subject’s trial 
spirometry through analysis of the flow-volume loop. Such approaches have the effect of reducing 
measurement variability and thus enhance the power of studies to detect therapy-related change in FVC.  
The last decade of IPF trials has also seen the development of more robust and sophisticated statistical 
methods for handling inevitable missing endpoint data. In large phase 3 clinical trials as many as 15-
20% of subjects can have missing primary endpoint data (Collard, 2010). This occurs principally 
because of death but also due to drop outs and because some patients are too unwell to undertake 
maneuvers such as spirometry. In early studies, such missing primary endpoint events were handled 
with one of two extremes, either carrying forward the last observation or assigning zero to deaths and, 
in some cases, also to values missing for reasons other than death. In trials where there are imbalances 
between arms in missing values these methods of handling missing data can either magnify or disguise 
the true differences between groups. To address this issue, the TOMORROW and INPULSIS studies 
moved away from using change from baseline in FVC at 12 months to using change in FVC decline 
over 12 months (Richeldi et al., 2011; Richeldi et al., 2014). This latter approach permits all FVC 
values recorded over the course of the study to be utilized in deriving a slope reflecting the rate of 
change in the FVC. This method, relying as it does on multiple measures and no imputation of missing 
data, is much less influenced by missing observations. This is borne out by the results of sensitivity 
analyses, which demonstrate that different methods of imputing missing data points had little influence 
on the observed rate of change between treatment arms in the two INPULSIS trials (Richeldi et al., 
2014).  
Cumulatively, international randomized controlled trials (RCTs) have now involved the participation of 
over 3,000 individuals with IPF. Whilst all of the trials conducted to date have assessed the role of 
specific drug therapies, an important added benefit of the prospective observation of large numbers of 













(Martinez et al., 2005). Prior to the advent of clinical trials, much of what was known about IPF had 
been derived from retrospective cohorts usually followed at dedicated tertiary centres. It has only been 
by following individuals with IPF prospectively that the true morbidity and mortality associated with 
acute exacerbations (AE) of IPF has been realized (Collard et al., 2007). Furthermore, insights derived 
from clinical trials have helped inform the current diagnostic approach to IPF, which has now been 
enshrined in updated international guidelines (Raghu et al., 2011). 
 
5. Recent phase 3 randomized controlled trials 
Pirfenidone. Pirfenidone, an orally administered pyridine, was initially identified as having analgesic, 
anti-inflammatory and anti-pyretic activities in animals. However, the unexpected identification of 
antifibrotic effects in animals redefined the interest in the compound (Lasky, 2004). Subsequently, 
pirfenidone has been shown both in in vitro experiments and in vivo animal models of pulmonary 
fibrosis to exert anti-fibrotic, antiinflammatory and anti-oxidant properties through down-regulation of 
profibrotic growth factors including platelet-derived growth factor (PDGF) and transforming growth 
factor (TGF)-β; inhibition of inflammatory cytokine (e.g., tumour necrosis factor [TNF]-α) production 
and release; and reduction of lipid peroxidation and oxidative stress (Iyer et al., 1999; Maher, 2010; 
Schaefer, 2011).The first promising effect in IPF patients was observed in a prospective, open-label 
phase 2 study published in 1999 (Raghu et al., 1999).  
The first RCT of pirfenidone in IPF was conducted in Japan by Azuma and co-workers (Azuma et al., 
2005). The study did not meet its primary end-point of change in lowest arterial oxygen saturation 
during a 6-minute walk test (6MWT), although at 9 months the rate of decline in vital capacity (VC) 
was significantly reduced in the treatment arm. Since the publication of this study, four phase 3 RCTs 













Taniguchi (Taniguchi et al., 2010). 275 Japanese patients (20-75 years of age) were randomly assigned 
in a 2:1:2 ratio to high-dose (1800 mg/day) or low-dose (1200 mg/day) pirfenidone, or placebo. The 
primary endpoint was the change in VC from baseline to week 52. The study met its primary outcome 
as the loss in VC was significantly higher in the placebo arm (-0.16 L) compared to both the high-dose 
(-0.09 L; p = 0.042) and low-dose pirfenidone arms (0.08 L; p = 0.039). High-dose pirfenidone was 
also associated with a significant improvement in PFS time compared to placebo (p = 0.028). 
Conversely, the incidence of acute exacerbations (either during the study of within 28 days after the 
termination of the study) did not differ among the high-dose (5.6%), low-dose (5.5%) and placebo 
(4.8%) groups.  
CAPACITY (Noble et al., 2011). The CAPACITY (Clinical Studies Assessing Pirfenidone in Idiopathic 
Pulmonary Fibrosis: Research of Efficacy and Safety Outcomes) program consisted of two almost 
identical multinational trials (PIPF-004 and PIPF-006). Eligible patients were aged 40-80 years with a 
diagnosis of IPF made in the previous 48 months. Inclusion criteria included a predicted FVC ≥50%, 
predicted diffusing capacity of the lung for carbon monoxide (DLCO) of ≥35%, either predicted FVC or 
predicted DLCO ≤90% and a 6MWT distance of at least 150 m. In study 004, 435 patients were 
assigned in a 2:1:2 dosing ratio to pirfenidone 2403 mg/day, pirfenidone 1197 mg/day, or placebo, 
whereas study 006 (n = 344) had only two treatment arms (pirfenidone 2403 mg/day and placebo). The 
primary endpoint of both trials was change in percentage predicted FVC from baseline to week 72. In 
study 004, mean FVC change at week 72 was -8.0% in the pirfenidone 2403 mg/day arm compared to -
12.4% in the placebo arm (p = 0.001). In addition, high-dose pirfenidone reduced the proportion of 
patients with FVC decline ≥10% compared to placebo (20% vs. 35%, respectively). A loss of ≥10% in 
FVC is a clinically meaningful event for an IPF patient as it translates into an increased rate of death of 
up to eight-fold in the following year (du Bois et al., 2011a). Study 006 did not meet its primary end 













identical (-9.0 and -9.6%, respectively). Of note, while the magnitude of decline in FVC over time was 
similar in the pirfenidone arms of 004 and 006 studies, the rate of decline in the placebo groups 
differed. Specifically, the placebo arm of study 006 experienced an attenuated FVC decline (-9.6%) 
compared to that observed in placebo arms of previous large RCTs in IPF (Ley et al., 2011). 
Pirfenidone 2403 mg/day prolonged PFS (time to confirmed ≥10% decline in percentage predicted 
FVC, ≥15% decline in percentage predicted DLCO or death) in study 004, but not in study 006. 
Conversely, pirfenidone 2403 mg/day significantly reduced decline in 6MWT distance in study 006, 
but not in study 004. The study by Taniguchi et al. and the two CAPACITY trials were of sufficient 
methodological quality to be included in a Cochrane systematic review and meta-analysis, which 
demonstrated that pirfenidone significantly reduces both the rate of lung function deterioration and the 
risk of disease progression in patients with IPF (Spagnolo et al., 2010). Based on these cumulative data, 
in 2011, pirfenidone was approved by the European Medicines Agency (EMA) for the treatment of 
patients with mild to moderate IPF (e.g., FVC >50%).  
ASCEND (King et al., 2014a). In ASCEND (Assessment of Pirfenidone to Confirm Efficacy and Safety 
in Idiopathic Pulmonary Fibrosis) 555 IPF patients were randomly assigned to either pirfenidone 2403 
mg/day (n = 278) or placebo (n = 277). Eligible patients were between the ages of 40 and 80 years and 
had received a centrally confirmed diagnosis of IPF. Additional inclusion criteria included a range of 
50% to 90% of the predicted FVC, a range of 30% to 90% of the predicted DLCO, a ratio of the forced 
expiratory volume in one second (FEV1) to the FVC of 0.80 or more and a 6MWT distance of at least 
150 m. The primary end point was change from baseline to week 52 in the percentage of predicted 
FVC. The study met its primary endpoint as assessed by a rank analysis of covariance (ANCOVA). 
Pirfenidone treatment also significantly reduced the proportion of patients who had a decline of 10% or 
more in the percentage predicted FVC or who died, and significantly increased  the proportion of 













31.8% [p<0.001], and 22.7% vs. 9.7% [p<0.001], respectively). In addition, pirfenidone significantly 
reduced the decline in the 6MWT distance (p = 0.04) and improved PFS (p<0.001). Furthermore, in a 
pre-specified pooled analysis incorporating data from ASCEND and the two CAPACITY studies, 
pirfenidone reduced all-cause mortality and IPF-related mortality at 1 year by 48% (p = 0.01) and 68% 
(p = 0.006), respectively, compared with placebo. Conversely, pirfenidone treatment had no effect on 
dyspnoea as assessed by the University of California San Diego Shortness of Breath Questionnaire. 
Consistent with the known safety profile of the drug, most common treatment-related adverse events 
were gastrointestinal upset and photosensitivity rash, which were generally mild to moderate in 
severity, reversible, and without clinically significant sequelae (Valeyre et al., 2014). 
 
Nintedanib. Formally known by the development code BIBF 1120, nintedanib is a potent intracellular 
inhibitor of fibroblast growth factor receptor (FGFR) 1, 2 and 3, platelet-derived growth factor receptor 
(PDGFR) α and β, and vascular endothelial growth factor receptor (VEGFR) 1, 2 and 3 (Hilberg et al., 
2008). It also inhibits the Src family tyrosine kinases Lck, Lyn and Flt-3 (Hilberg et al., 2008). 
Nintedanib was originally developed as an angiostatic factor for cancer treatment, and is approved for 
lung cancer patients with advanced adenocarcinoma after first-line chemotherapy. In addition, it is 
currently being investigated in ovarian (phase 3), Fallopian tube (phase 2), thyroid (phase 2), peritoneal 
(phase 2), prostate (phase 2), liver (phase 2), renal (phase 2) and colorectal (phase 2) cancer as well as 
myeloma (phase 1). However, nintedanib has also been shown to exert anti-fibrotic activities in 
bleomycin-induced pulmonary fibrosis in rodents (Chaudhary et al., 2007; Wollin et al., 2014). In 
primary human lung fibroblasts from patients with IPF, nintedanib inhibits FGF-, PDGF- and VEGF-
induced profibrotic effects, reduces TGF-β-induced collagen deposition, and inhibits TGF-β-induced 













TOMORROW (Richeldi et al., 2011). In this phase 2b study, the TOMORROW (To Improve 
Pulmonary Fibrosis With BIBF 1120),  432 patients with IPF were treated with one of four escalating 
doses of nintedanib (50 mg once a day, and 50 mg, 100 mg, or 150 mg all twice a day) or placebo for 
52 weeks. Eligible patients were 40 years of age or older and had received a centrally confirmed 
diagnosis of IPF less than 5 years before screening. Additional inclusion criteria included a FVC of 
50% or more of the predicted value and a DLCO that was 30% to 79% of the predicted value. The 
primary end point was the annual rate of decline in FVC.  While the study did not achieve statistical 
significance (because of the hierarchical testing procedure adopted with correction for multiplicity), in 
the group receiving 150 mg twice a day FVC declined by 0.06 liters per year as compared to 0.19 liters 
per year in the placebo group, corresponding to a 68.4% reduction in the rate of loss. Moreover, the 
proportion of patients who had a decrease in FVC >10% or >200 ml was smaller in the highest-dose 
group than in the placebo group (23.8% vs. 44.0%; p = 0.004). Additional beneficial effects of 
nintedanib 150 mg twice daily compared to placebo included a lower incidence of AE of IPF (2.4 vs. 
15.7 per 100 patient-years, respectively) and a significantly improved quality of life as assessed by St. 
George’s Respiratory Questionnaire (SGRQ). Specifically, there were improvements in two domains of 
the SGRQ - symptoms and activity. Adverse events lead to study discontinuation in 25.9%, 23.3%, 
16.3%, 14.0% and 30.6% of patients in the placebo, 50 mg once daily, 50 mg twice daily, 100 mg twice 
daily and 150 mg twice daily groups, respectively.  
INPULSIS (Richeldi et al., 2014). The INPULSIS 1 and INPULSIS 2 were two parallel phase 3 studies 
that evaluated the efficacy and safety of nintedanib at the dose of 150 mg twice daily compared with 
placebo in patients with IPF. Patients were eligible if they were 40 years of age or older and had 
received a centrally confirmed diagnosis of IPF within the previous 5 years. Additional eligibility 
criteria included a FVC of 50% or more of the predicted value and a DLCO that was 30% to 79% of the 













placebo (309 vs. 204 in INPULSIS 1 and 329 vs. 219 in INPULSIS 2, respectively). The primary end 
point was the annual rate of decline in FVC.  Both trials met their primary outcome. In fact, the 
adjusted annual rate of change in FVC was -115 ml among patients on nintedanib and -240 ml among 
patients on placebo in INPULSIS 1 (difference: 125 ml; p<0.001) and -114 ml and -207 ml in 
INPULSIS 2 (difference: 93 ml; p<0.001), respectively. In addition, in both trials a significantly greater 
proportion of patients in the placebo arm than in the nintedanib arm had an absolute decline in the 
percentage of predicted FVC >5% at week 52. As for the two key secondary endpoints, change in 
quality of life (as assessed by SGRQ) was non-significant in INPULSIS 1 (p = 0.97) but significant in 
INPULSIS 2 (p = 0.02), whereas time to the first AE-IPF was significant in INPULSIS 2 (p = 0.005) 
but not in INPULSIS 1 (p = 0.67). However, a pre-specified sensitivity analysis of pooled data on the 
time to the first adjudicated AE (confirmed or suspected) showed that nintedanib had a significant 
benefit as compared with placebo. Finally, in a pre-specified pooled analysis, no significant difference 
in death from any cause (5.5% in the nintedanib group vs. 7.8% in the placebo group; p = 0.14) or 
death from a respiratory cause was observed, although these trials were not powered to detect 
statistically significant differences in mortality. Overall, nintedanib showed an acceptable safety profile. 
The most frequent drug-related adverse event in both trials was diarrhoea (with rates of 61.5% and 
18.6% in the nintedanib and placebo groups, respectively, in INPULSIS 1 and 63.2% and 18.3% in the 
two groups, respectively, in INPULSIS 2). However, the majority of events were of mild or moderate 
intensity and most patients continued to receive nintedanib for the duration of the treatment period.  
 
N-acetylcysteine. N-acetylcysteine (NAC) is a small molecule that acts as a scavenger for reactive 
oxidative species. NAC was first reported to have clinical benefit in the early 1960s, when it was 
shown to be an effective mucolytic agent in patients with cystic fibrosis (Hurst et al., 1967). Other 













overdose, prevention of chronic obstructive pulmonary disease exacerbation and prevention of contrast-
induced kidney damage during imaging procedures (Millea 2009). In addition, NAC is commonly used 
as a nutritional supplement. 
An oxidant-antioxidant imbalance is believed to play a role in the pathogenesis of IPF based on the 
finding that levels of the endogenous antioxidant glutathione (GSH) are markedly reduced in the lungs 
of patients (Cantin et al., 1989). The observation that high-dose oral NAC increases lung levels of GSH 
and improves lung function in patients with fibrosing alveolitis (Behr et al., 1997), paved the way for 
the IFIGENIA trial (Idiopathic Pulmonary Fibrosis International Group Exploring N-Acetylcysteine), a 
double-blind, randomized, placebo-controlled multicenter study that assessed the efficacy over one 
year of high-dose NAC (600 mg three times daily) added to prednisone and azathioprine (which at that 
time was the standard therapy) in patients with IPF (Demedts et al., 2005). As compared with standard 
therapy (the “placebo” arm), triple therapy (NAC/prednisone/azathioprine) significantly slowed the 
decline of both VC and DLCO (the primary end points), as assessed by change between baseline and 
month 12. Although positive, this study had important drawbacks, mainly related the lack of a survival 
benefit (though the study was not powered for mortality), the use of the last observation carried 
forward (LOCF) method of analysis, which inflates type I error (e.g., it may overestimate the treatment 
effect), and the high rate of patients who did not complete the treatment period (about 30%). The 
IPFnet-sponsored PANTHER study (Prednisone, Azathioprine, and N-acetylcysteine: A Study That 
Evaluates Response in IPF) was specifically designed to address some of the issues raised by the 
IFIGENIA trial and to test the assumption that prednisolone and azathioprine should be considered 
“standard of care” for patients with IPF (Idiopathic Pulmonary Fibrosis Clinical Research Network, 
2012). Patients in the study were randomized in a 1:1:1 ratio to NAC/prednisone/azathioprine (triple 
therapy), NAC alone or placebo. Unexpectedly, a pre-specified efficacy and safety interim analysis 













compared with placebo, was associated with a statistically significant increase in all-cause mortality, 
all-cause hospitalizations, and treatment-related severe adverse events, thus strongly arguing against 
the use of this treatment approach in patients with IPF. The combination therapy arm was therefore 
terminated early and PANTHER continued as a two-group study (i.e., NAC vs. placebo). The 
completed study did not meet its primary outcome of change in FVC over a 60-week period. In fact, 
FVC decline over the study period was -0.18 litres in the NAC arm and -0.19 litres in the placebo arm 
(p = 0.77) (Idiopathic Pulmonary Fibrosis Clinical Research Network, 2014). Similarly, NAC was not 
superior to placebo in reducing the rates of death or AE of IPF. Moreover, a significant increase in 
serious cardiac events was observed in the NAC arm compared to placebo (6.8% versus 1.5%, 
respectively). 
 
6. What have we learned from positive studies? Implications on better understanding of disease 
pathogenesis 
Basic IPF research has long suffered a disconnect from IPF clinical practice. Over the last couple of 
decades, pre-clinical studies, usually conducted in vitro in fibroblasts or in vivo in the rodent bleomycin 
model, have uncovered multiple abnormalities in a range of key wound healing cascades all of which 
appear to be capable of driving the development of fibrosis (Maher et al., 2007). Whilst these insights 
have been mechanistically interesting, there has been a failure to link individual abnormalities to the 
development or progression of human fibrotic disease. Redundancy and pleiotropism of signalling 
pathways undoubtedly means that many receptor or growth factor abnormalities, which appear to 
promote or inhibit fibrosis in mice are of limited importance in human disease. Furthermore, the major 
tool used in pre-clinical assessment of candidate therapeutics has tended to be the bleomycin model. As 
has already been alluded to, unlike IPF, which is a progressive fibrotic disorder with minimal 













epithelial cell apoptosis and accompanying inflammatory cell influx and tends to be self-limiting with 
partial resolution after about 28 days (Maher and Wells, 2009; Moeller et al., 2008). 
So, with these issues in mind does the recent success of pirfenidone and nintedanib in clinical trials 
teach us anything about IPF pathogenesis and, if so, will these insights help pave the way for more 
rationale IPF drug discovery in the future? The answer to these questions is not entirely straightforward. 
Nintedanib’s principal action is on the receptors for VEGF, PDGF and FGF (Chaudhary et al., 2007). 
All of these growth factors have been previously implicated in the development of pulmonary fibrosis 
and so the efficacy of nintedanib in IPF, to a certain extent, validates previous pre-clinical observations. 
Pirfenidone has effects on multiple signalling cascades, presumably through kinase inhibition, but it 
remains unclear whether pirfenidone has a single key target or whether its effects derive from its broad 
spectrum of action. Relatively little pre-clinical data has been published on the in vitro or in vivo effects 
of either nintedanib or pirfenidone in fibrosing disease. Both drugs have, however, been shown to be 
effective in reducing bleomycin-induced fibrosis in rodents when dosed therapeutically and so provide 
a degree of validation for this model
 
(Chaudhary et al., 2007; Oku et al., 2008; Kakugawa et al., 2004). 
Whilst these drugs confirm that fibrosis can be ameliorated through abrogation of wound healing 
pathways, neither compound really provides a way of better designing or informing in vitro fibrosis 
research. Accordingly, further pre-clinical studies are required before it will be possible to derive major 
pathogenic insights from the therapeutic effects of either nintedanib or pirfenidone. Both drugs do, 

















The results of recently completed clinical trials in IPF have tremendous implications in clinical 
practice. Warfarin was considered a therapeutic option for a minority of IPF patients based on the 
results of an open label study conducted in Japan showing that anticoagulant therapy significantly 
reduces mortality associated with AE (Kubo et al., 2005). Yet, the study had important methodological 
limitations, including absence of blinding; significant withdrawal rate in the anticoagulant group (26%; 
e.g., it is possible that patients who left the study were more ill and would have had higher mortality); 
and unusually high incidence of AE (57% overall and 64% in the placebo group). A double-blind, 
randomized, placebo-controlled study (the AntiCoagulant Effectiveness in Idiopathic Pulmonary 
Fibrosis [ACE-IPF]) was therefore specifically designed to evaluate the efficacy of anticoagulation in 
IPF (Noth et al., 2012). However, the ACE study was terminated early (after 145 of the planned 256 
subjects were enrolled) due to excess mortality in the warfarin arm (14 warfarin vs. 3 placebo deaths; 
adjusted hazard ratio = 4.85). Warfarin treatment was also associated with an increase in all-cause and 
respiratory-related hospitalizations, and AE of IPF, strongly arguing against the use of warfarin for 
treating patients with IPF. Accordingly, recommendations on the use of anticoagulants in IPF will soon 
change. Similarly, the demonstration that previously recommended “standard-of-care” 
(prednisone/azathioprine/NAC) is actually associated with increased mortality, excess of 
hospitalizations and increased serious adverse events compared to placebo has already impacted 
dramatically the approach to treatment of IPF patients (Idiopathic Pulmonary Fibrosis Clinical 
Research Network, 2012). While formal recommendations have not yet been produced, most 
physicians no longer initiate immunosuppressive therapy in newly diagnosed patient with IPF and have 
chosen to withdraw such treatment in patients initiated on immunosuppression prior to announcement 
of the PANTHER data in October 2011. However, in patients who have demonstrated sustained 













fibrotic nonspecific interstitial pneumonia or chronic hypersensitivity pneumonitis is in the differential 
diagnosis) the decision regarding the use of immunosuppression is now far from straightforward. 
The implications of the PANTHER study, which showed that NAC is ineffective in slowing the rate of 
FVC decline in patients with IPF, are less predictable (Idiopathic Pulmonary Fibrosis Clinical Research 
Network, 2014). According to current guidelines, acetylcysteine monotherapy may represent a 
reasonable therapeutic choice for a minority of patients  (Raghu et al., 2011). Yet, in clinical practice 
NAC is widely used, mainly in patients with “severe” IPF (e.g., FVC <50%), or in those not eligible for 
enrolment in a clinical trial. However, the recent approval by the FDA of both pirfenidone and 
nintedanib for the same indication and with no restriction based on disease severity will likely limit 
further the use of NAC monotherapy (e.g., to patients who are unable to tolerate either drug or for 
whom they are contraindicated).  
 
8. Open questions 
The results of the INPULSIS 1 and INPULSIS 2 and the ASCEND trials represent a major 
breakthrough for patients with IPF. Based on the results of these studies it is likely that clinicians and 
patients will soon have genuine choices when it comes to selecting pharmacological therapy for IPF. In 
addition, there is now indirect evidence demonstrating that reducing the rate of functional decline in 
IPF (as measured by serial change in FVC) translates into a reduced rate of mortality. In fact, a pre-
specified analysis of the pooled population of the ASCEND and CAPACITY studies (n = 1,247 
patients) showed that pirfenidone, as compared with placebo, reduces both all-cause and IPF-related 
mortality (King et al., 2014a). Similarly, nintedanib treatment resulted in a trend toward a reduced 
mortality mirroring the slowing of functional deterioration (Richeldi et al., 2014). Nevertheless, these 
data should be viewed as a starting point in the search for better IPF treatments especially as a number 













Confidence in clinical response and interpretation of results in therapeutic trials of IPF. There are 
many considerations and challenges involved in the design and completion of a treatment trial in IPF, 
including heterogeneity in disease progression and uncertainty regarding the optimal outcome measures, 
which make it difficult to be confident of a robust clinical response. Indeed, IPF patients progress and 
lose lung function at different rates, whereas approximately two-thirds of them do not show FVC 
decline over the course of a one-year trial. Accordingly, while categorical change in FVC is a more 
informative metric of clinical meaningfulness than group mean, efficacy endpoints are driven by only a 
subgroup of patients (e.g., those who experience progression over the course of the clinical trial), 
although progression may be continuous yet undetectable using common clinical tests. A cohort 
enrichment strategy allowing for more homogeneous study populations who experience an increased 
number of events would reduce substantially the size of the study population and the duration of the 
trial, thus allowing the timely, successful completion of the study. An alternative approach for enabling 
the event rate would be the implementation of composite endpoints, which ideally should be 
constituted by quantifiable measures that reflect a spectrum of pathophysiological consequences of 
disease progression (Kaul et al., 2010). However, at present, there are no universally accepted 
composite end-points in IPF. Survival is probably the only indisputable endpoint in a deadly disease 
like IPF, but a properly powered mortality study in patients with mild to moderate functional 
impairment is impracticable due to the number of patients and length of trial needed (King et al., 
2014b). Mortality studies might be best suited for patients with advanced disease, or rapid progressors, 
which would offer the theoretical advantage of higher event rates, smaller sample size and shorter trial 
duration. However, the disease is not well characterized in this population and there are insufficient 
reliable data to estimate the appropriate sample size and study duration (King et al., 2014b). 
Severe IPF. The complexity of the diagnostic process in IPF makes misdiagnosis and delayed diagnosis 













advanced disease and severe functional impairment (percentage of the predicted FVC <50%). Yet, 
ASCEND, CAPACITY and INPULSIS all limited their enrollment to patients with mild-to-moderate 
functional impairment (e.g., percentage of the predicted FVC >50%). The assumption behind such 
restricted criteria, which are adopted for most IPF clinical trials, is mainly that advanced disease is less 
likely to be amenable to any anti-fibrotic therapy, although there are no convincing data in this regard, 
and that these patients may have different and unpredictable response rates and more frequent and 
severe adverse events. Therefore, although the FDA has approved both pirfenidone and nintedanib 
regardless of disease severity (and nintedanib has also been approved by the EMA with the same 
indication), we cannot know with certainty at the moment whether these drugs are also safe and 
efficacious in individuals with advanced disease.  
Patients without a diagnosis of “definite IPF”. According to the 2011 evidence-based guidelines, 
patients presenting with non-diagnostic chest CT scans require a confirmatory surgical lung biopsy. 
However, in clinical practice, surgical lung biopsy is performed in only a minority of patients, either 
because of the risks associated with the procedure - particularly in elderly subjects - or because of the 
reluctance of most individuals to undergo surgery (Raghu et al., 2011). Moreover, albeit in a minority 
of cases, even the availability and integration of clinical, radiological, and histologic data may not be 
sufficient to establish a secure diagnosis of IPF. Such patients (e.g., those with a “probable” or 
“possible” IPF) are commonly excluded from clinical trials - which require a definite diagnosis of IPF - 
although the INPULSIS trials allowed a proportion of them to enroll (Richeldi et al., 2014). It is 
therefore uncertain whether the results of clinical trials undertaken in patients with definite IPF also 
apply to those with “probable” or “possible” IPF.  
Comorbid Disease. IPF is frequently accompanied (or complicated) by common comorbid conditions, 
which contribute to its poor prognosis and impaired quality of life (Fell, 2012). In addition, the 













disease often preclude IPF patients from participating in clinical trials. In clinical practice, the 
management of such patients is the most challenging, and solid, prospective data on which to make 
recommendations for treatment of concomitant conditions in patients with IPF are urgently needed. 
A minority of patients are eligible to clinical trials. With very few exceptions, clinical trials in IPF have 
enrolled selected patients (e.g., those with mild-to-moderate functional impairment), in whom the rates 
of functional decline and disease progression are both relatively low and variable (King et al., 2014a; 
Richeldi et al., 2014). Many patients are excluded mainly due to their age, disease severity, or 
comorbidities, while rapid progressors might have failed inclusion criteria by the time they got access 
to the trial, thus highlighting the difficulty in accruing adequate numbers of eligible patients within a 
reasonably short period of time (Nathan et al., 2011). It is important that, in future, clinical trials seek 
to enrol a broader and more representative population of patients with IPF. Only by doing so will it be 
possible for clinicians to have confidence in the clinical applicability of data generated in randomised 
controlled trials of novel IPF therapies. 
 
9. Conclusions 
Clinical research on pharmacological treatment of IPF has until very recently witnessed repeated 
failure and with it a growing sense of frustration. Improved knowledge of disease pathogenesis coupled 
with the availability of compounds with pleiotropic anti-fibrotic properties is finally changing the 
landscape of IPF treatment. However, slowing the deterioration of lung function and reducing disease 
progression in patients with mild-to-moderate IPF, which is undoubtedly a major achievement, should 
be viewed as a new starting point. In fact, a number of key questions remain unanswered: do the 
beneficial effect of pirfenidone and nintedanib also apply to patients who fall outside the inclusion 
criteria of these trials or to patients with other forms of fibrosing lung disease? Do these compounds 













who will progress rapidly or those more likely to respond to a specific treatment? These questions 
notwithstanding, the IPF community now has a platform on which to build treatments which are, at last, 
able to alter the natural history of this devastating disease.  
 
This manuscript has not been published and is not under consideration for publication elsewhere. 
 
Conflict of interest statement: 
Dr Paolo Spagnolo serves as consultant for Roche. In the last three years PS has served as consultant 
for Chiesi and has received consulting fees from Boehringer Ingelheim and speaker’s fees from 
InterMune and Boehringer Ingelheim;  
Dr Toby M. Maher is in receipt of unrestricted academic industry grants from GSK, UCB and Novartis. 
In the last three years TM or his institution have received advisory board or consultancy fees from; 
Boehringer Ingelheim, Bayer, Biogen, ProMedior, GSK, InterMune, Novartis, Lanthio, Roche, Takeda, 
Sanofi-Aventis and UCB. TM has received speaker's fees from UCB, Boehringer Ingelheim, InterMune 
and AstraZeneca. TM has participated as an investigator in industry sponsored clinical trials run by 
Boehringer Ingelheim, Gilead, GSK, InterMune, Novartis, Roche and Celgene; 
Prof Luca Richeldi has received grants for research and fees for lectures, advisory board meetings, and 
steering committee meetings from InterMune, Boehringer Ingelheim, Roche, Takeda, Shionogi, Biogen 
Idec, Sanofi-Aventis, MedImmune and ImmuneWorks. 
 
Figure legend 
Figure 1. Usual interstitial pneumonia (UIP) pattern in a patient with idiopathic pulmonary fibrosis 
(IPF). High-resolution CT shows a characteristic combination of peripheral, subpleural, and 
predominantly basilar reticular abnormalities with associated honeycomb change (arrows) and traction 
bronchiectasis.  
 
Figure 2. Usual interstitial pneumonia (UIP) pattern. UIP is characterized by a patchy geographical 
distribution (spatial heterogeneity) of the fibrotic process alternating relatively preserved lung (arrows) 
and fibrosis (circles). Temporal heterogeneity refers to areas of early, active fibrosis (so-called 
«fibroblastic foci»; asterisk) abruptly akin to old, established fibrosis (diamond). Extensive 
lymphoplasmacytic inflammation is generally absent. Hematoxylin-eosin 40X. Courtesy Giulio Rossi 
MD (University Hospital of Modena, Italy).  
 
Figure 3. Honeycomb change. Areas of honeycomb change are composed of cystic fibrotic air spaces 
(*), which are frequently lined by bronchiolar epithelium and filled with mucin (#). Smooth muscle 
hyperplasia is commonly seen in areas of fibrosis and honeycomb change. Hematoxylin-eosin 40X. 
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Table 1. Recommendations on pharmacological treatment of IPF according to current guidelines 
 Recommendation 
 For Against 
Strength of the recommendation  Weak Strong Weak Strong 
Quality of evidence L/VL M/H L/VL M/H L/VL M/H L/VL M/H 
Therapeutic agent  
Azathioprine + corticosteroids       X  
Azathioprine + corticosteroids + NAC*     X    
Bosentan        X 
Colchicine       X  
Corticosteroids alone       X  
Cyclosporin A       X  
Cyclophosphamide + corticosteroids       X  
Etanercept        X 
Interferon-γ-1b        X 
NAC alone*     X    
Pirfenidone*     X    
Warfarin*     X    
 
(Modified from Raghu et al., 2011) 
 
L: low; VL: very low; M: medium; H: high 
NAC: N-acetylcysteine; 
 
*Recommendations on these therapeutic options will change in the near future based on the results of recent clinical trials 
 
Note: official recommendations on the use of imatinib, sildenafil, ambrisentan and nintedanib in patients with IPF are not 















    Table 2. Overview of negative phase II and phase III randomized controlled trials in IPF 
 
 




Primary endpoint / 





prednisone + NAC vs. 





Change in FVC over 60 weeks 
N = 236 
The combination-therapy arm 
was terminated early due to 
increased rate of death and 
hospitalization. No physiological 
or clinical benefit for 
combination therapy. No effect of 
NAC in reducing FVC decline. 
(Idiopathic Pulmonary 
Fibrosis Clinical Research 
Network, 2012;  
Idiopathic Pulmonary 
Fibrosis Clinical Research 
Network, 2014) 
Etanercept TNF inhibitor 
Changes from baseline in 
FVC % predicted, DLCO % 
predicted and P(A-a)O2 at rest 
over 48 weeks 
N = 88 
No differences in the predefined 
endpoints 
(Raghu et al., 2008) 
Everolimus 
mTOR inhibitor - 
proliferation signal 
inhibitor 
Time to disease progression 
(time to the second of any two 
of 10% decline in FVC or TLC, 
15% decline in DLCO, 4% 
decline in room air oxygen 
saturation) 
N = 89 
Everolimus treatment was 
associated with increased disease 
progression and higher frequency 
of adverse events 





Change in FVC from baseline 
up to month 12 
N = 178 
No difference between treatments 
in pulmonary function tests, or 
time to disease worsening or 
death 
(Raghu, et al., 2013b) 
Interferon gamma-1b  
 
Anti-inflammatory, 
antifibrotic and pro-Th1 
Progression-free survival 
(defined as the time to disease 
progression or death) 
N = 330 
No effect on progression-free 
survival, pulmonary function or 
quality of life 
(Raghu et al., 2004)  
Interferon gamma-1b  
- INSPIRE 
Anti-inflammatory, 
antifibrotic and pro-Th1 
Overall survival 
N = 826 
The study was terminated at the 
second interim analysis due to 
lack of benefit compared with 
placebo 





Proportion of patients with an 
increase in the 6-minute walk 
distance of ≥20% 
N = 180 
The study enrolled patients with 
advanced IPF (DLCO <35% of the 
predicted value). 
No benefit for sildenafil for the 
primary outcome 
(Idiopathic Pulmonary 





Composite endpoint (time to 
death, hospitalization or ≥10% 
decline in FVC) 
N = 145 
The study was terminated early 
due to increased mortality in the 
warfarin arm. 
(Noth et al., 2012) 
Bosentan 
- BUILD-1 
Dual endothelin receptor 
antagonist 
Change from baseline up to 
month 12 in exercise capacity, 
as measured by 6MWT 
N = 158 
No superiority of bosentan over 
placebo in the primary endpoint. 
(King et al., 2008) 
Bosentan 
- BUILD-3 
Dual endothelin receptor 
antagonist 
Time to IPF worsening (decline 
in FVC ≥10% and decline in 
DLCO ≥15% or acute 
exacerbation) or death 
N = 616 
No difference between treatment 
groups in the primary endpoint 
analysis. 
(King, et al., 2011b) 
Ambrisentan 
- ARTEMIS 
Endothelin A receptor 
antagonist 
Time to disease progression 
(death, decline in FVC ≥10%, 
decline in DLCO ≥15% or acute 
exacerbation) 
N = 492 
The study was terminated early 
due to increased risk for disease 
progression and hospitalization. 
 
(Raghu, et al., 2013a) 
Imatinib 
PDGFR-α and -β 
inhibitor 
Time to disease progression 
(10% decline in FVC from 
baseline) or death 
N = 119 
No effect of imatinib on survival 
or lung function. 
(Daniels et al., 2010) 
Co-trimoxazole Antibiotic 
Change in FVC over 1 year 
N = 181 
Only 89% of patients had 
definite/probable IPF. 
Co-trimoxazole was added to 
standard treatment. 
No effect on lung function 
(Shulgina et al., 2013) 
 













DLCO: diffusing capacity of the lung for carbon monoxide; FVC: forced vital capacity; mTOR: mammalian target of rapamycin; NAC: N-acetylcysteine; 
P(A-a)O2: alveolar to arterial oxygen pressure difference; PDGFR: platelet-derived growth factor receptors; 6MWT: six-minute walk test; TLC: total lung 
capacity; TNF: tumour necrosis factor.  
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